Select Publications

Chung CH et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha- 1,3-galactose. N Engl J Med 2008;358(11):1109-17. Abstract

Heymach JV et al. Randomized, placebo-controlled Phase II study of vandetanib plus
docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol 2007;25(27):4270- 7. Abstract

Manegold C et al. (AVAIL): A Phase III randomised study of first-line bevacizumab
combined with cisplatin/gemcitabine in patients with advanced or recurrent nonsquamous, non-small-cell-lung cancer. Proc ESMO 2008;Abstract LBA1.

Natale RB et al. ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial. Proc ASCO 2006;Abstract 7000.

Pirker R et al. FLEX: A randomized, multicenter, phase III study of cetuximab in
combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). Proc ASCO 2008;Abstract 3.

Ramalingam SS et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol  2008;26(1):60-5. Abstract

Sandler AB et al. Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonary hemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer (NSCLC). Proc ASCO 2008;Abstract 8074.

Home

EDITOR
Neil Love, MD

INTERVIEWS

David Jablons, MD
- Select publications

Gregory J Riely, MD, PhD
- Select publications

Alan B Sandler, MD
- Select publications

David S Ettinger, MD
- Select publications

Lung Cancer Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office